Bortezomib- and carfilzomib-resistant multiple myeloma cells generated in vitro match the molecular hallmarks of bortezomib-resistant primary myeloma cells, but differ in their sensitivity to bortezomib, carfilzomib and novel proteasome inhibiting drugs

Saved in:
Bibliographic Details
Published inClinical lymphoma, myeloma and leukemia Vol. 15; pp. e232 - e233
Main Authors Besse, L, Besse, A, Florea, B.I, Soriano, G.P, Bader, J, Overkleeft, H, Kraus, M, Driessen, C
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.09.2015
Subjects
Hematology, Oncology and Palliative Medicine
Online AccessGet full text

Cover

More Information
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2015.07.496